Sign In
Buy MRK
$115.17
+0.270 (+0.235%)
At Close: Jun 16, 2026
Where Merck & Co Stands With Analysts
07:06pm, Wednesday, 06'th Apr 2022 Benzinga
Analysts have provided the following ratings for Merck & Co (NYSE:MRK) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
3
1
0
0
Last 30
Top Analyst Reports for Merck, CVS Health & American Tower
04:39pm, Wednesday, 06'th Apr 2022 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Merck & Co. Inc. (MRK), CVS Health Corporation (CVS), and American Tower Corporation (AMT).
Clovis (CLVS) Up 24% on Upbeat Data From Ovarian Cancer Study
07:11pm, Monday, 04'th Apr 2022 Zacks Investment Research
Clovis Oncology's (CLVS) stock price rises after it reports favorable data from a late-stage study on Rubraca as the first-line maintenance treatment of ovarian cancer.
Can Merck (MRK) Keep the Earnings Surprise Streak Alive?
04:10pm, Monday, 04'th Apr 2022 Zacks Investment Research
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Merck's (MRK) Pneumococcal Vaccine sBLA Faces FDA Delay
02:40pm, Monday, 04'th Apr 2022 Zacks Investment Research
Merck's (MRK) Vaxneuvance vaccine includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
2 Drugmakers Set for Explosive Revenue This Decade
10:00am, Sunday, 03'rd Apr 2022 The Motley Fool
They are selling much-needed products.
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
07:16pm, Friday, 01'st Apr 2022 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
U.S. lawmakers close to agreeing on $10 billion in funding for next phase of the COVID-19 battle, as death toll tops 980,000
06:33pm, Friday, 01'st Apr 2022 MarketWatch
U.S. lawmakers moved close to agreeing on a bipartisan compromise to provide a fresh $10 billion to combat COVID-19 on Thursday, a deal that could set up final congressional approval next week.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
01:51pm, Thursday, 31'st Mar 2022 Zacks Investment Research
Corcept (CORT) posts overall survival data from a phase II study evaluating relacorilant plus nab-paclitaxel for treating recurrent platinum-resistant ovarian cancer.
CNBC's Final Trades: Merck, Royal Caribbean Cruises And This Energy Play
12:39pm, Thursday, 31'st Mar 2022 Benzinga
On CNBC’s “Halftime Report Final Trades,” Jon Najarian said there was “unusual activity” in Royal Caribbean Cruises Ltd (NYSE: RCL). “I bought that,” he added.
Joseph Terranova of Virtus
3 of the Best Value Stocks to Buy Heading Into April
03:07pm, Wednesday, 30'th Mar 2022 The Motley Fool
With these shares at modest valuations, you can score some cheap long-term investments.
5 Charts That Show Why Bristol-Myers Squibb Is a No-Brainer Buy
02:15pm, Wednesday, 30'th Mar 2022 The Motley Fool
The company gives investors plenty of reasons to buy and hold the stock for years.
Bristol Myers (BMY) Application for Opdivo With Chemo Validated
03:38pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Bristol Myers (BMY) type II variation application for Opdivo in combination with chemotherapy for the neoadjuvant treatment of patients with non-small cell lung cancer gets EMA validation.
2 Dirt Cheap Dividend Stocks to Buy Right Now
03:00pm, Tuesday, 29'th Mar 2022 The Motley Fool
These two bargain stocks look like steals right now.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
12:50pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
